[logo] HealthTree Foundation
search person
chevron_left Bispecific Antibodies to Treat Multiple Myeloma: An Educational Guide

Infection Prevention (2/4)

Last updated on: 10/18/2024

COVID-19 and bispecific antibody therapy

The risk of severe COVID-19 complications and death for patients receiving bispecific antibody therapy has significantly decreased due to advancements in:

  • Antiviral prophylaxis: Effective antiviral medications can now be used preventatively to significantly reduce the chances of developing severe COVID-19 infection.
  • Immunoglobulin replacement therapy (IVIG): For patients with low immunoglobulin levels, intravenous immunoglobulin infusions can further strengthen their immune system and help them fight infections, including COVID-19.
  • The COVID-19 vaccine (typically all myeloma patients receive this vaccination).